Post-earnings recap
Reported
Wed, Nov 10, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edgewise Therapeutics reported a wider-than-expected loss for the quarter, which contributed to a 2.21% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's focus on pipeline development suggests they are prioritizing long-term growth despite current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | -16.59% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific guidance for future performance.
The company is focused on advancing its pipeline despite the current challenges.